WEDNESDAY, (HealthDay News) — The active ingredient in a drug that’s expected to become a popular Multiple Sclerosis Treatment has been linked to four European cases of a rare but sometimes fatal brain disease called progressive multifocal leukoencephalopathy (PML).The ingredient, dimethyl fumarate, is used in a drug called Fumaderm that was approved in Germany in 1994 to treat the skin condition psoriasis. It is also in a different but closely related medication called Tecfidera, which was just approved by the U.S. Food and Drug Administration in March for Multiple Sclerosis Treatment.

It is known as a fumaric acid ester, which is commonly used as a food additive and has been used to treat psoriasis in Germany for 30 years.According to reports published in the April 25 issue of the New England Journal of Medicine, however, three patients who were taking Fumaderm to treat their psoriasis developed PML. One other patient developed the brain condition after taking a separate medication from a compounding pharmacy that also contained dimethyl fumarate.

Prev1 of 4
Continue Reading on Next Page


Leave A Reply